drugset / Trial / NCT01950182
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine Therapy.
Timeline
- Start
- 2013-09-16
- Primary completion
- 2020-05-31
- Completion
- 2020-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |
| Comparator | Capecitabine | Small molecule | — | — |
| Subject | Exemestane | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Tamoxifen | Small molecule | — | — |
| Comparator | Vinorelbine | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |